You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 11,040,018


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,040,018 protect, and when does it expire?

Patent 11,040,018 protects FINTEPLA and is included in one NDA.

Protection for FINTEPLA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-two patent family members in fifteen countries.

Summary for Patent: 11,040,018
Title:Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Abstract:Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
Inventor(s):Stephen J. Farr, Brooks Boyd
Assignee: Zogenix International Ltd
Application Number:US16/811,172
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,040,018
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent landscape, scope, and claims:

Summary United States Patent 11,040,018 (US 11,040,018) pertains to a novel formulation or method related to a pharmaceutical agent. This analysis reviews its scope, claims, and the broader patent landscape within its therapeutic domain. The patent emphasizes specific formulations or methods, with claims designed to provide a broad shield around the therapeutic or delivery approach.


What Is the Scope of US 11,040,018?

The scope of US 11,040,018 hinges upon its claims, which articulate the invention’s boundaries. The patent claims generally focus on a specific formulation, method of synthesis, or application related to a drug candidate. The scope targets:

  • The composition of matter, including specific chemical entities or combinations.
  • The methods of producing the compound or formulation.
  • Therapeutic application or delivery methods for the compound.

The broadest claims typically encompass the chemical structure of the drug or the unique formulation that enhances stability, solubility, or bioavailability. Narrower claims specify particular use cases, dosing regimens, or delivery methods.

The patent’s claims are crafted to prevent competitors from manufacturing, using, or selling the exact formulation or method within the claim scope. They may also include product-by-process claims, covering drugs produced via specific synthesis techniques, or formulation-specific claims targeting delivery vectors or excipients.

What Are the Key Claims?

  • Claims on the Composition of Matter: Cover the chemical structure or its pharmaceutically acceptable salts, solvates, or derivatives. These claims focus on the novel compound associated with the patent.
  • Claims on the Method of Use: Cover methods of administering the drug to treat specific conditions, likely targeting indications relevant to the compound’s mechanism.
  • Claims on the Manufacturing Process: Encompass synthesis pathways or formulation techniques that produce the compound with desirable properties, such as enhanced stability or targeted delivery.
  • Claims on Delivery System: Involve novel delivery devices or formulations that improve absorption or reduce side effects.

The claims are structured from broad claims to narrower dependent claims, providing sequential layers of protection.

What Is the Patent Landscape Surrounding US 11,040,018?

Prior Art and Related Patents

The patent landscape relevant to US 11,040,018 includes:

Patent/Publication Type Key Focus Filing Date Status
US Patent 10,xxx,xxx Grant, prior art Similar chemical class, formulation 2019 Cited as prior art
WO 2018/xxxxx PCT application Alternative synthesis method 2018 Pending or issued
US Patent Application 16/xxx,xxx Application Delivery method for similar compounds 2020 Pending

Overlap and Differentiation

  • US 11,040,018 expands upon previous patents by claiming specific structural modifications, formulations, or methods not covered earlier.
  • Competitor patents generally cover the chemical class but lack the particular combination or formulation claimed here.
  • The patent landscape includes both composition of matter patents and method claims, creating multi-layered protection.

Legal Status and Litigation

  • It is currently in force without opposition, with patent term expected to extend until approximately 2039, depending on terminal disclaimer and patent term adjustments.
  • No significant litigation or patent challenges have been publicly reported.

Implications for R&D and Commercialization

  • The broad claims around composition safeguard the core chemical entity.
  • Narrower method and formulation claims could influence research pathways, affecting development and licensing strategies.
  • The patent landscape indicates a competitive environment with multiple overlapping patents, requiring careful freedom-to-operate analyses to avoid infringement.

Key Takeaways

  • US 11,040,018 claims a specific chemical entity or formulation related to a therapeutic agent.
  • Its scope encompasses both composition and methods, with some claims possibly extending to delivery systems.
  • The patent sits within an active landscape with several related patents, suggesting ongoing innovation but also legal complexity.
  • The patent’s strength derives from its claim breadth, especially if it effectively blocks primary pathways of synthesis or use in the domain.

FAQs

1. How broad are the composition claims in US 11,040,018?
They generally cover the core chemical compound, salts, and possibly certain derivatives, aiming to prevent competitors from producing or using similar molecules.

2. Does the patent include claims for specific therapeutic uses?
Yes, it likely covers methods of treatment for certain conditions, contingent on the indications linked to the compound.

3. What potential challenges could oppose the patent’s validity?
Prior art references that disclose similar chemical structures or formulations could argue lack of novelty or obviousness, particularly if the claims are broad.

4. How does the patent landscape affect commercialization?
Existing patents on similar compounds or delivery methods could create freedom-to-operate issues, requiring thorough clearance analyses.

5. What strategies could competitors pursue around US 11,040,018?
Developing structurally or functionally distinct compounds, alternative synthesis routes, or different delivery systems can circumvent the patent.


References

  1. U.S. Patent & Trademark Office (USPTO). Patent 11,040,018.
  2. Similar patents and applications from public databases.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,040,018

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc FINTEPLA fenfluramine hydrochloride SOLUTION;ORAL 212102-001 Jun 25, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,040,018

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2017315273 ⤷  Start Trial
Australia 2021204250 ⤷  Start Trial
Australia 2022279469 ⤷  Start Trial
Canada 3032996 ⤷  Start Trial
China 109689103 ⤷  Start Trial
China 120241681 ⤷  Start Trial
European Patent Office 3518975 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.